DLL3 car-t therapy for recurrent brain tumors
Part of Cancer clinical trials.
This trial tests a new immune therapy called DLL3 CAR-T cells for people with brain tumors that have come back or not responded to treatment. It aims to see if these specially designed cells can attack the tumor safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 70 years old.
- You have a brain tumor that has come back or not responded to standard treatment, and you have a measurable tumor.
- Your overall health is fairly good (score of 60 or higher on a standard health scale).
- You are not taking high doses of steroids (dexamethasone 4 mg or less per day).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You do not have HIV, active tuberculosis, an autoimmune disease, or severe allergies, and you are not in another immune cell trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Hear when a new Glioblastoma of Cerebellum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.